Dr Yelena Janjigian speaks to ecancer about the final overall survival and key outcomes from the MATTERHORN trial, a global, double-blind phase 3 study evaluating durvalumab plus FLOT chemotherapy versus placebo plus FLOT in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

Dr Janjigian says that durvalumab and FLOT significantly improved overall survival compared with placebo and FLOT (HR 0.78; p=0.021), regardless of PD-L1 status.

This treatment regimen also showed higher rates of nodal clearance (ypN-) and improved event-free survival (EFS) were observed in patients achieving pathological complete response (pCR), major pathological response (MPR), or any pathological response (pR).

The study shows that durvalumab combined with FLOT offers better survival outcomes and improved pathological responses without being limited by PD-L1 expression, marking a significant advancement in perioperative therapy for resectable gastric and GEJ cancer.